285 related articles for article (PubMed ID: 23787550)
1. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
Covic A; Passlick-Deetjen J; Kroczak M; Büschges-Seraphin B; Ghenu A; Ponce P; Marzell B; de Francisco AL
Nephrol Dial Transplant; 2013 Sep; 28(9):2383-92. PubMed ID: 23787550
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
[TBL] [Abstract][Full Text] [Related]
3. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
[TBL] [Abstract][Full Text] [Related]
4. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
5. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
[TBL] [Abstract][Full Text] [Related]
6. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
7. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF; Chen YM; Hung KY; Chu TS; Kan WC; Huang CY; Lin SL; Kao TW; Huang JW; Chiang WC; Yen CJ; Tsai TJ; Wu KD; Wu MS
J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
9. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
10. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
12. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
13. A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.
Neven E; De Schutter TM; Dams G; Gundlach K; Steppan S; Büchel J; Passlick-Deetjen J; D'Haese PC; Behets GJ
PLoS One; 2014; 9(9):e107067. PubMed ID: 25229549
[TBL] [Abstract][Full Text] [Related]
14. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
17. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
18. Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up.
de Francisco AL; Belmar L; Piñera C; Kislikova M; Seras M; Serrano M; Albines Z; Sango C; Arias M
Nefrologia; 2014; 34(5):617-27. PubMed ID: 25259817
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
Hervás JG; Prados D; Cerezo S
Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]